Actinium is developing a pipeline of Antibody Radiation Conjugates for targeted conditioning and combination therapies.

Actinium Pharmaceuticals, Inc.

Actinium Pharmaceuticals, Inc. | 13,072 followers on LinkedIn. Targeted Therapies for Patients with Unmet Needs | Actinium Pharmaceuticals (NYSE: ATNM) is focused on developing innovative targeted radioimmunotherapies for the treatment of advanced cancers. Currently Investigating therapies in #AML and #BMT

Vice President, Patent and Legal Counsel at Actinium Pharmaceuticals, Inc.

Paul Diamond

Biotech Executive | Finance & Operations | Biotech Growth Specialist | Vice President, Finance @ Actinium Pharmaceuticals

Steve Dressel

Gary Siegel

Chief Business Officer

Lynn Bodarky

Actinium Pharmaceuticals (NYSE: ATNM) Appoints Accomplished Biopharma Industry Executive June Almenoff, M.D., Ph.D. to its Board of Directors. Read the press release here: https://bit.ly/4eftEdy

Actinium Pharmaceuticals Announces Publication of Results from the Phase 3 SIERRA Trial of Iomab-B in the Journal of Clinical Oncology. Read the press release here: https://bit.ly/3MOAuf4 #AML #Radiotherapies

Actinium Provides Regulatory Update on Planned BLA Filing and Future Plans for Iomab-B in the U.S. Read the press release here: https://bit.ly/3Ad5jXP

Actinium Expands Patent Coverage Over Iomab-ACT, its Next-Generation Targeted #Radiotherapy Conditioning Agent, for Gene Edited Stem Cell-Based Therapies for Non-Malignant Indications. Read the press release here: https://bit.ly/3A2I02C #CARTcelltherapy #CellTherapy

Actinium (NYSE: ATNM) Announces FDA Clearance of Iomab-ACT Targeted Conditioning IND Application for #SickleCellDisease Patients Undergoing #BoneMarrowTransplant in Collaboration with Columbia University. Read the press release here: https://bit.ly/3A8BnvC #BMT

Actinium Pharmaceuticals (NYSE: ATNM) to Present at the 3rd Annual Targeted Radiopharmaceuticals Summit US. Read the press release here: https://bit.ly/3YfmQZ9 #Radiotherapy

#EHA2024 recap: Abstract detailing the first ever preclinical data from the combination of menin inhibitors with Actinium's ARC Actimab-A in acute myeloid leukemia (AML) models. Results available here: https://bit.ly/3VJRDLX

#EHA2024 presentation recap: median overall survival of 5.49 months observed in patients with a TP53 mutation receiving an Iomab-B led allogeneic #bonemarrowtransplant compared to 1.66 months in patients that did not receive Iomab-B in Phase 3 SIERRA Trial. More details here: https://lnkd.in/gBJF3HT3

Actimab-A is an ARC comprised of a CD33 targeting monoclonal antibody conjugated with the alpha-particle emitter Actinium-225 isotope payload. Read recent data presented at #SNMMI24 as we advance our Actimab program: https://bit.ly/3Ro0ikZ

Actinium recently announced the long-term efficacy results in patients with active relapsed or refractory acute myeloid leukemia also observed in the Phase 3 SIERRA trial. Read more here: https://bit.ly/3VqCTQL #Oncology #EHA2024 #Radiotherapies

Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.

Actinium Pharmaceuticals, Inc

news_impact_assignment_basic

key_people

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

merger_acquisitions

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general	Nov 12, 2024 9:14 AM	760d0e68
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general	Nov 12, 2024 9:14 AM	bab39713
crunchbase trigger	general	Nov 12, 2024 9:14 AM	7108f9e7
crunchbase profile	general
li profile	general	Nov 12, 2024 9:14 AM	8621d0b8
translate crunchbase fundingrounds	general
peers	general	Nov 12, 2024 9:14 AM	0b837e98
news basic	general	Nov 12, 2024 9:14 AM	c35041a7
bundesanzeiger	filings
merger acquisitions	company_analysis
financials download nd	financials
private financials	financials

COM:ACTINIUMPHARMA

Actinium Pharmaceuticals, Inc.

Last Close

1.39

21/11 21:00

Market Cap

45.86M

Beta: -

Volume Today

277.25K

Avg: -